Today President Biden signed into law H.R. 2471, the “Consolidated Appropriations Act, 2022”, which was passed by the House and Senate last week. The omnibus package notably includes:
- $110 million for the Peer-reviewed Prostate Cancer Research Program at the Department of Defense
- $14.2 million for Prostate Cancer at the Centers for Disease Control and Prevention (CDC)
- $44.96 billion for the National Institutes of Health (NIH), including $6.9 billion for the National Cancer Institute (NCI)
Since PCF’s inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease.
PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. To date, PCF has also committed $50 million in philanthropic funding to establish 13 VA centers of excellence that deliver innovative, best-in-class prostate cancer research, treatment, and care to Veterans given the burden of prostate cancer among Veterans. PCF has also partnered with the National Institutes of Health to launch and champion a $26.5 million study called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress.
PCF is also member of the larger community of advocates who champion federal medical research progress including coalitions and working groups.
Featured Sign-on Letters Related to Fiscal Year 2022 Appropriations